Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic myeloid leukemia markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.03% during 2024-2034.
The chronic myeloid leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic myeloid leukemia (CML) refers to a form of tumor that affects the bone marrow and blood. It is mainly characterized by the uncontrolled growth of immature white blood cells (myeloid cells) in the bone marrow. The illness typically progresses slowly, and in the early phases, patients may not experience any symptoms. As the disease advances, some common indications may include fatigue, weight loss, abdominal swelling or discomfort, anemia, an enlarged spleen, reduced ability to exercise, easy bleeding or bruising, shortness of breath, etc. Individuals suffering from CML may also experience fever, pain in the bones, itching, a feeling of fullness, excessive sweating at night, etc. The diagnosis of this ailment involves a combination of medical history assessment, physical examination, and various laboratory tests. During a physical investigation, the medical practitioner will initially check for any signs of enlarged organs. A cytogenetic analysis is also recommended to identify the presence of abnormal chromosomes in the blood or bone marrow cells. Numerous blood workups, like a complete blood count and peripheral blood smear tests, are utilized to confirm a diagnosis among patients.
The increasing incidence of chromosomal abnormalities on account of genetic mutations, which promote the overgrowth of white blood cells, is primarily driving the chronic myeloid leukemia market. Additionally, the expanding geriatric population, who are more susceptible to age-related decline in the immune system that affects the body's ability to prevent the development of cancerous cells, is also propelling the market growth. Besides this, the emerging popularity of tyrosine kinase inhibitors, such as imatinib, dasatinib, nilotinib, etc., which work by blocking the action of specific faulty proteins in the body to treat tumors, is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of immunotherapy, like interferon-alpha, for regulating the immune response and suppressing the spread of leukemia cells is also creating a positive outlook for the market. Apart from this, the escalating application of stem cell transplants that involve the replacement of diseased bone marrow with healthy stem cells in patients who have not responded to other pharmacological treatments is expected to drive the chronic myeloid leukemia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic myeloid leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic myeloid leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic myeloid leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic myeloid leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic myeloid leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic myeloid leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic myeloid leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic myeloid leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic myeloid leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic myeloid leukemia across the seven major markets?
What is the size of the chronic myeloid leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic myeloid leukemia?
What will be the growth rate of patients across the seven major markets?
Chronic Myeloid Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic myeloid leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic myeloid leukemia market?
What are the key regulatory events related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by status related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by phase related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by route of administration related to the chronic myeloid leukemia market?
The chronic myeloid leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Myeloid Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic myeloid leukemia (CML) refers to a form of tumor that affects the bone marrow and blood. It is mainly characterized by the uncontrolled growth of immature white blood cells (myeloid cells) in the bone marrow. The illness typically progresses slowly, and in the early phases, patients may not experience any symptoms. As the disease advances, some common indications may include fatigue, weight loss, abdominal swelling or discomfort, anemia, an enlarged spleen, reduced ability to exercise, easy bleeding or bruising, shortness of breath, etc. Individuals suffering from CML may also experience fever, pain in the bones, itching, a feeling of fullness, excessive sweating at night, etc. The diagnosis of this ailment involves a combination of medical history assessment, physical examination, and various laboratory tests. During a physical investigation, the medical practitioner will initially check for any signs of enlarged organs. A cytogenetic analysis is also recommended to identify the presence of abnormal chromosomes in the blood or bone marrow cells. Numerous blood workups, like a complete blood count and peripheral blood smear tests, are utilized to confirm a diagnosis among patients.
The increasing incidence of chromosomal abnormalities on account of genetic mutations, which promote the overgrowth of white blood cells, is primarily driving the chronic myeloid leukemia market. Additionally, the expanding geriatric population, who are more susceptible to age-related decline in the immune system that affects the body's ability to prevent the development of cancerous cells, is also propelling the market growth. Besides this, the emerging popularity of tyrosine kinase inhibitors, such as imatinib, dasatinib, nilotinib, etc., which work by blocking the action of specific faulty proteins in the body to treat tumors, is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of immunotherapy, like interferon-alpha, for regulating the immune response and suppressing the spread of leukemia cells is also creating a positive outlook for the market. Apart from this, the escalating application of stem cell transplants that involve the replacement of diseased bone marrow with healthy stem cells in patients who have not responded to other pharmacological treatments is expected to drive the chronic myeloid leukemia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic myeloid leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic myeloid leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic myeloid leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic myeloid leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic myeloid leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic myeloid leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic myeloid leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic myeloid leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic myeloid leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic myeloid leukemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic myeloid leukemia across the seven major markets?
What is the size of the chronic myeloid leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic myeloid leukemia?
What will be the growth rate of patients across the seven major markets?
Chronic Myeloid Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic myeloid leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic myeloid leukemia market?
What are the key regulatory events related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by status related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by phase related to the chronic myeloid leukemia market?
What is the structure of clinical trial landscape by route of administration related to the chronic myeloid leukemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC MYELOID LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC MYELOID LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC MYELOID LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC MYELOID LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC MYELOID LEUKEMIA - UNMET NEEDS
10 CHRONIC MYELOID LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC MYELOID LEUKEMIA - MARKETED PRODUCTS
11.1 List of Chronic Myeloid Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Sprycel (Dasatinib) - Bristol-Myers Squibb
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Tasigna (Nilotinib) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bosulif (Bosutinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Iclusig (Ponatinib) - Takeda Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Scemblix (Asciminib) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC MYELOID LEUKEMIA - PIPELINE DRUGS
12.1 List of Chronic Myeloid Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 KRT 232 - Kartos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ELVN 001 - Enliven Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Vodobatinib - Sun Pharma Advanced Research Company
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 SAR 445419 - Sanofi
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AOP2014 - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC MYELOID LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC MYELOID LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC MYELOID LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Myeloid Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Myeloid Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Myeloid Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Myeloid Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Myeloid Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Myeloid Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Myeloid Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Myeloid Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
16 CHRONIC MYELOID LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC MYELOID LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC MYELOID LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC MYELOID LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC MYELOID LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC MYELOID LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC MYELOID LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC MYELOID LEUKEMIA - UNMET NEEDS
10 CHRONIC MYELOID LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC MYELOID LEUKEMIA - MARKETED PRODUCTS
11.1 List of Chronic Myeloid Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Sprycel (Dasatinib) - Bristol-Myers Squibb
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Tasigna (Nilotinib) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bosulif (Bosutinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Iclusig (Ponatinib) - Takeda Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Scemblix (Asciminib) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC MYELOID LEUKEMIA - PIPELINE DRUGS
12.1 List of Chronic Myeloid Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 KRT 232 - Kartos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ELVN 001 - Enliven Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Vodobatinib - Sun Pharma Advanced Research Company
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 SAR 445419 - Sanofi
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AOP2014 - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC MYELOID LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC MYELOID LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC MYELOID LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Myeloid Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Myeloid Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Myeloid Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Myeloid Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Myeloid Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Myeloid Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Myeloid Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Myeloid Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Myeloid Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Myeloid Leukemia - Access and Reimbursement Overview
16 CHRONIC MYELOID LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC MYELOID LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC MYELOID LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
